De novo protein design
Computationally designing proteins with new structures and functions, such as binders, enzymes and molecular machines, that work on the first or second try.
State of the art
Diffusion-based design tools (RFdiffusion, 2023) and the 2024 Nobel Prize in Chemistry for computational protein design.
- Designing catalysis and conformational dynamics
Who’s working on it
- David BakerResearcherInstitute for Protein Design, University of Washington
Shared the 2024 Nobel Prize in Chemistry for computational protein design; his lab released RFdiffusion (2023) and RFantibody, the generative methods most of the field now builds on
- Institute for Protein Design ↗Academic lab
University of Washington centre that produces the open design tools and has spun out more than twenty protein-design companies
- Xaira Therapeutics ↗Startup
Launched in 2024 with roughly $1B from ARCH and Foresite, co-founded by David Baker, to run de novo design end to end with its own perturbation and virtual-cell data
- Generate:Biomedicines ↗Company
Its AI-designed long-acting anti-TSLP antibody GB-0895 moved into two global Phase 3 asthma trials in approximately 1,600 patients (announced December 2025), the furthest-advanced generatively designed protein
- EvolutionaryScale ↗Startup
Built the ESM3 protein language model (98B parameters) and used it to generate esmGFP, a fluorescent protein far outside the natural sequence neighbourhood (2024)
- Google DeepMindCompany
AlphaFold made structure prediction routine and AlphaProteo (2024) extended the group into de novo binder design, raising the baseline every other team is measured against
What to invest in
| Kind | Investment | Scale |
|---|---|---|
| research | High-throughput design–test loops for enzymes and molecular machines | $$ $10M – $100M |
Depends on
A root node: no prerequisites modeled.